PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance

The Immune Revolution: A Case for Priming, Not Checkpoint

(2018) Robert H. Vonderheide   CANCER CELL

CD38-NAD + Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response

(2018) Shilpak Chatterjee et al.   Cell Metabolism

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

(2018) Daniela S. Thommen et al.   NATURE MEDICINE

High response rate to PD-1 blockade in desmoplastic melanomas

(2018) Zeynep Eroglu et al.   NATURE

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

(2018) Peng Jiang et al.   NATURE MEDICINE

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

(2018) Moshe Sade-Feldman et al.   CELL

Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation

(2018) Zachary S. Buchwald et al.   Frontiers in Oncology

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Chromatin states define tumour-specific T cell dysfunction and reprogramming

(2017) Mary Philip et al.   NATURE

Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors

(2017) Alexandra-Chloé Villani et al.   SCIENCE

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

(2017) Rajeev K. Shrimali et al.   Cancer Immunology Research

Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses

(2017) Nikolaos Patsoukis et al.   Frontiers in Immunology

Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis

(2016) Andrea Schietinger et al.   IMMUNITY

Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer

(2016) Yaqi Li et al.   Molecular Cancer

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Functional role of T-cell receptor nanoclusters in signal initiation and antigen discrimination

(2016) Sophie V. Pageon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy

(2016) Natalie A. Vandeven et al.   Journal of Oncology Practice

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

(2015) Kevin C. Soares et al.   JOURNAL OF IMMUNOTHERAPY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Prognostic and predictive value of PDL1 expression in breast cancer

(2015) Renaud Sabatier et al.   Oncotarget

Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+T-cell proliferation and survival

(2015) Rasha Abu Eid et al.   OncoImmunology

Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody

(2014) L. Karyampudi et al.   CANCER RESEARCH

Identification of the Genomic Insertion Site of Pmel-1 TCR α and β Transgenes by Next-Generation Sequencing

(2014) Yun Ji et al.   PLoS One

Immune Modulation in Cancer with Antibodies

(2013) David B. Page et al.   Annual Review of Medicine

TCR activation kinetics and feedback regulation in primary human T cells

(2013) Mateusz Poltorak et al.   Cell Communication and Signaling

Checkpoint blocking antibodies in cancer immunotherapy

(2013) Chrisann Kyi et al.   FEBS LETTERS

Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy

(2013) Mikayel Mkrtichyan et al.   Journal for ImmunoTherapy of Cancer

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

B7-DC-Ig Enhances Vaccine Effect by a Novel Mechanism Dependent on PD-1 Expression Level on T Cell Subsets

(2012) M. Mkrtichyan et al.   JOURNAL OF IMMUNOLOGY

Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms

(2011) Mikayel Mkrtichyan et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cell metabolism: An essential link between cell growth and apoptosis

(2010) Emily F. Mason et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Signaling defects in anti-tumor T cells

(2008) Alan B. Frey et al.   IMMUNOLOGICAL REVIEWS

Selective expansion of a subset of exhausted CD8 T cells by  PD-L1 blockade

(2008) S. D. Blackburn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA